Picture of Anthem Biosciences logo

ANTHEM — Anthem Biosciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Nomura initiates coverage on India's Anthem Biosciences with 'buy'; shares rise

** Nomura initiates coverage on Anthem Biosciences ANTH.NS with "buy," target price of 740 rupees - representing an 18% premium on last close

** Shares of ANTH rise as much as 3.6% to 651 rupees, last up ~1%

** Nomura says ANTH can sustain 17% growth in CY24–29, outpacing industry’s 13% growth in the contract research, development and manufacturing organisation segment

** Adds, co has a wider customer base and a strong "fee for service" strategy vs peers

** Anthem's stable leadership with employee attrition below peers has led strong operating performance with industry-leading profit margins and return ratios - Nomura

** Believes ANTH's key molecules' growth, new launches and capacity expansion are key positives for medium-term growth

** ANTH down 13% since listing on July 21

 (Reporting by Manvi Pant)

 ((Manvi.Pant@thomsonreuters.com; +918447554364;))

Recent news on Anthem Biosciences

See all news